Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 3, May-June, p. 505–511

doi: 10.17219/acem/62398

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco

Marek Z. Wojtukiewicz1,2,A,C,E,F, Ewa Sierko1,2,A,B,C,D,E,F, Piotr Skalij1,2,B,D,F, Magda Kamińska1,2,B,D,F, Lech Zimnoch3,C,F, Ralf A. Brekken4,A,F, Philip E. Thorpe5,A,F

1 Department of Oncology, Medical University of Bialystok, Poland

2 Comprehensive Cancer Center, Białystok, Poland

3 Department of Pathomorphology, Medical University of Bialystok, Poland

4 Department of Pharmacology, UT-Southwestern Medical Center, Dallas, TX, USA

5 Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX, USA

Abstract

Background. Doxorubicin and docetaxel-based chemotherapy regimens used in breast cancer patients are associated with high risk of febrile neutropenia (FN). Granulocyte colony-stimulating factors (G-CSF) are recommended for both treating and preventing chemotherapy-induced neutropenia. Increased thrombosis incidence in G-CSF treated patients was reported; however, the underlying mechanisms remain unclear. The principal activator of blood coagulation in cancer is tissue factor (TF). It additionally contributes to cancer progression and stimulates angiogenesis. The main proangiogenic factor is vascular endothelial growth factor (VEGF).
Objectives. The aim of the study was to evaluate granulocyte-colony stimulating factor receptor (G-CSFR), tissue factor (TF) expression and vascular endothelial growth factor receptor (VEGF-R) bound VEGF in human breast cancer in loco.
Material and Methods. G-CSFR, TF and VEGFR bound VEGF (VEGF: VEGFR) were assessed in 28 breast cancer tissue samples. Immunohistochemical (IHC) methodologies according to ABC technique and double staining IHC procedure were employed utilizing antibodies against G-CSFR, TF and VEGF associated with VEGFR (VEGF: VEGFR).
Results. Expression of G-CSFR was demonstrated in 20 breast cancer tissue specimens (71%). In 6 cases (21%) the expression was strong (IRS 9–12). Strong expression of TF was observed in all investigated cases (100%). Moreover, expression of VEGF: VEGFR was visualized in cancer cells (IRS 5–8). No presence of G-CSFR, TF or VEGF: VEGFR was detected on healthy breast cells. Double staining IHC studies revealed co-localization of G-CSFR and TF, G-CSFR and VEGF: VEGFR, as well as TF and VEGF: VEGFR on breast cancer cells and ECs.
Conclusion. The results of the study indicate that GCSFR, TF and VEGF: VEGFR expression as well as their co-expression might influence breast cancer biology, and may increase thromboembolic adverse events incidence.

Key words

breast cancer, neutropenia, granulocyte colony stimulating factor, tissue factor, vascular endothelial growth factor receptor

References (43)

  1. Leśniczak B, Krasomski G, Oszukowski P, Stetkiewicz T, Woźniak P: Incidence of and mortality from breast cancer among women in Poland in the years 2001–2010. Prz Menopauzalny 2014, 13, 344–347.
  2. Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH: The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: A prospective cohort study. Springerplus 2015, 4, 396. Published online 2015 Aug 6. DOI: 10.1186/s40064-015-1165-6.
  3. Chirivella I, Bermejo B, Insa A, Pérez-Fidalgo A, Magro A, Rosello S, García-Garre E, Martín P, Bosch A, Lluch A: Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patient. Breast Cancer Res Treat 2009, 114, 479–484.
  4. Milam MR1, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT: Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2011, 21, 66–71.
  5. Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV: The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: A meta-analysis. Breast Cancer Res Treat 2015, Sep 4. [Epub ahead of print]
  6. Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N: Comparison of EP2006, a filgrastim biosimilar, to the reference: A phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2015, 26, 1948–1953.
  7. Zheng R, Han S, Duan C, Chen K, You Z, Jia J, Lin S, Liang L, Liu A, Long H, Wang S: Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: A meta-analysis of randomized trials. Medicine (Baltimore) 2015, 94, e803.
  8. Stricker H: Venous thromboembolism and cancer: Pathophysiology and incidence. Vasa 2014, 43.4, 239–243.
  9. Larsen A, Davis T, Curtis BM, Gimpel S, Sims JE, Cosman D, Park L, Sorensen E, March CJ, Smith CA: Expression cloning of a human granulocyte colony-stimulating factor receptor: A structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med 1990, 172, 1559–1570.
  10. Manz MG, Miyamoto T, Akashi K, Weissman IL: Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A 2002, 99, 11872–11877.
  11. Wojtukiewicz MZ, Sierko E, Kisiel W: The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 2007, 33, 621–642.
  12. Sierko E, Wojtukiewicz MZ, Kisiel W: The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007, 33, 653–659.
  13. Thaler J, Koppensteiner R, Pabinger I, Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T: Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res 2014, 134, 1093–1096.
  14. Koizume S, Miyagi Y: Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets. World J Clin Oncol 2014, 5, 908–920.
  15. Patel KR, Vajaria BN, Begum R, Patel JB, Shah FD, Joshi GM, Patel PS: VEGFA isoforms play a vital role in oral cancer progression. Tumour Biol 2015, Mar 25. [Epub ahead of print]
  16. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A: A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med 2014, 3, 737–746.
  17. Prager GW, Poettler M, Unseld M, Zielinski CC: Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res 2012, 1, 14–25.
  18. Yadav L, Puri N, Rastogi V, Satpute P, Sharma V: Tumour Angiogenesis and Angiogenic Inhibitors: A Review. J Clin Diagn Res 2015, 9, XE01–XE05.
  19. Kowanetz M, Ferrara N: Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006, 12, 5018–5022.
  20. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99, 11393–11398.
  21. Kopparapu PK1, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL: Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 2013, 33, 2381–2390.
  22. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE: VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010, 17, 499–512.
  23. Brekken RA, Thorpe PE: VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Rel 2001, 74, 173–181.
  24. Brekken RA, Huang X, King SW, Thorpe PE: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998, 58, 1952–1959.
  25. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W: Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 2010, 103, 198–204.
  26. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994, 121, 492–501.
  27. Jones A, Fujiyama C, Hague S, Bicknell R: Assessment of angiogenic factors the chick chorioallantoic membrane assay. Methods Mol Med 2001, 58, 119–124.
  28. Welti J, Loges S, Dimmeler S, Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013, 123, 3190–3200.
  29. Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49, 507–521.
  30. Shen BQ, Lee DY, Cortopassi KM, Damico LA, Zioncheck TF: Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem 2001, 276, 5281–5286.
  31. Bluff JE, Brown NJ, Reed MW, Staton CA: Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 2008, 10, 204.
  32. Koomagi R, Volm M: Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis. Int J Cancer 1998, 79, 19–22.
  33. Ohta S, Wada H, Nakazaki T, Maeda Y, Nobori T, Shiku H, Nakamura S, Nagakawa O, Furuya Y, Fuse H: Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002, 22, 2991–2996.
  34. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994, 94, 1320–1327.
  35. Andrikopoulos P, Kieswich J, Harwood SM, Baba A, Matsuda T, Barbeau O, Jones K, Eccles SA, Yaqoob MM: Endothelial Angiogenesis and Barrier Function in Response to Thrombin Require Ca2+ Influx through the Na+/Ca2+ Exchanger. J Biol Chem 2015, 290, 18412–18428.
  36. Wojtukiewicz MZ, Sierko E, Klement P, Rak J: The hemostatic system and angiogenesis in malignancy. Neoplasia 2001, 3, 371–384.
  37. Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renaud C, Walz DA, Honn KV: Solid tumor express functional “tethered ligand” thrombin receptor. Cancer Res 1995, 55, 698–704.
  38. Yang XD, Huang P, Wang F, Xu ZK: Expression of granulocyte colony-stimulating factor receptor in rectal cancer. World J Gastroenterol 2014, 20, 1074–1078.
  39. Obermueller E, Vosseler S, Fusenig NE, Mueller MM: Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004, 64, 7801–7812.
  40. Nagy JA, Dvorak AM, Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007, 2, 251–275.
  41. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, Yoshizawa Y: Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999, 79, 472–477.
  42. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br J Cancer 2000, 83, 164–170.
  43. Mackman N: Role of tissue factor in hemostasis; thrombosis, and vascular development. Arterioscler Thromb Vascl Bio 2004, 24, 1015–1022.
© Wroclaw Medical University